ClinicalTrials.gg
CompletedNCT01547299Updated Oct 23, 2018Results posted

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

A Phase 2 interventional study of Enzalutamide and Leuprolide in Prostate Cancer, sponsored by Pfizer. Completed at 4 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
63rd of 125
52 · median 52
Started
2012
with 4 others
Phase 2
65 of 125
8 open now
Registered
11th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 5 that started in 2012, is one of 65 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • prostatectomy
  • neoadjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to provide
  • 18 years of age or older
  • confirmed adenocarcinoma of the prostate
  • Must be a candidate for radical prostatectomy and considered surgically resectable

Exclusion criteria

Exclusion Criteria:

  • Stage T4 prostate cancer by clinical or radiologic evaluation
  • Treatment with an agent within 4 weeks prior to randomization
  • Received therapy for other neoplastic disorders within 5 years
  • Hypogonadism or severe androgen deficiency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Enzalutamide alone

    Enzalutamide 160 mg, orally, once daily

    Drug: Enzalutamide

  • Experimental
    Enzalutamide & Leuprolide & Dutasteride

    Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily

    Drug: Enzalutamide · Drug: Leuprolide · Drug: Dutasteride

Interventions

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response Rate

    Pathologic complete response rate was defined as percentage of participants with pathologic complete response. Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 180 days prior to prostatectomy in participants with localized prostate cancer. Pathologic complete response was defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as assessed by the local and central pathologist.

    Time frame: Day 180

Secondary outcomes

  1. Percentage of Participants With Positive Surgical Margins

    To determine the percentage of participants with positive surgical margins at prostatectomy as assessed by the local and central pathologist. Surgical margin, also known as tumor free margin referred to the visible normal tissue or skin margin that was removed with the surgical excision of a tumor, growth, or malignancy. The margin was described as positive when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed.

    Time frame: Day 180

  2. Percentage of Participants With Extracapsular Extension: Local Review

    To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the local pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.

    Time frame: Day 180

  3. Percentage of Participants With Extracapsular Extension: Central Review

    To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the central pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.

    Time frame: Day 180

  4. Percentage of Participants With Positive Seminal Vesicles

    To determine the percentage of participants with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist. Seminal vesicles or seminal glands, were defined as a pair of simple tubular glands located within the pelvis. They secrete fluid that partly composes the semen. Seminal vesicles with cancer cells in them were called positive seminal vesicles.

    Time frame: Day 180

  5. Percentage of Participants With Positive Lymph Nodes

    To determine the percentage of participants with positive lymph nodes at prostatectomy as assessed by the local and central pathologist. Lymph nodes were small clumps of immune cells that act as filters for the lymphatic system. Lymph nodes with cancer cells in them were called positive lymph nodes.

    Time frame: Day 180

  6. Prostate-Specific Antigen (PSA) Nadir

    To determine the effects on PSA as measured by the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.

    Time frame: Day 195

  7. Time to Prostate-Specific Antigen (PSA) Nadir

    To determine the effects on PSA as measured by the time to the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.

    Time frame: Day 195

  8. Percentage of Participants With Reduction in Prostate-Specific Antigen (PSA)

    To determine the effects on PSA as measured by the percentage of participants with PSA less than (\<) 0.2 nanogram per milliliter (ng/mL), and a 50 percent (%) and 90% decrease in PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland.

    Time frame: Day 195

  9. Health-Related Quality of Life (HRQoL): Number of Participants With The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score

    EPIC sexual domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. Sexual domain summary score was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function and satisfaction. Best change from baseline category in EPIC sexual domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  10. Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score

    EPIC sexual function subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual function subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function. Best change from baseline category in EPIC sexual function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  11. Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score

    EPIC sexual bother subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual bother subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing less sexual bother and difficulty. Best change from baseline category in EPIC sexual bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  12. Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score

    EPIC Hormonal Domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  13. Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score

    EPIC hormonal function subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal function subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  14. Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score

    EPIC hormonal bother subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal bother subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing less hormonal bothering. Best change from baseline category in EPIC hormonal bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

    Time frame: Day 180

  15. Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 General Health Domain Score

    The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The general health domain score contained 1 item scored on a scale of 1 to 5 where 1=excellent to 5=poor health, where higher score indicated worse health status. Best change from baseline category in general health domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

    Time frame: Day 180

  16. Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Physical Functioning Domain Score

    The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The physical functioning domain score contained 2 items each scored on a scale of 1 to 5 where 1=excellent physical functioning to 5=poor physical functioning. Physical functioning domain total score ranged from 1 to 10, where higher scores indicated poor physical functioning. Best change from baseline category in physical functioning domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

    Time frame: Day 180

  17. Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Role-Emotional Domain Score

    The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5, where higher scores indicated worse mental status. The total score ranged from 1 to 10, where higher scores indicated worse mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

    Time frame: Day 180

  18. Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Mental Component Summary

    The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5 where for 1 item 1=all of the time person felt calm and peaceful to 5=none of the time person felt calm and peaceful. The score ranged from 1 to 5, where higher scores meant worse mental status. For other item 1=all of the time person felt downhearted and blue to 5=none of the time person felt downhearted and blue. The score ranged from 1 to 5, where higher scores meant better mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

    Time frame: Day 180

  19. Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)

    To determine pharmacodynamic effects as measured by the amount of tissue DHT in prostatectomy specimens following radical prostatectomy.

    Time frame: Day 180

  20. Pharmacodynamic Effects: Tissue Testosterone

    To determine pharmacodynamic effects as measured by the amount of tissue testosterone in prostatectomy specimens following radical prostatectomy.

    Time frame: Day 180

  21. Pharmacodynamic Effects: Assessment of Apoptosis

    To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens. Apoptosis was a process of biochemical events that lead to characteristic cell changes and death.

    Time frame: Day 180

  22. Pharmacodynamic Effects: Assessment of Mitotic Index

    Assessment was performed to determine the effects of triplet therapy and enzalutamide alone on mitotic index. Mitotic index was defined as the ratio between the numbers of cells in a population undergoing mitosis to the number of cells in a population not undergoing mitosis in prostatectomy specimens.

    Time frame: Day 180

  23. Pharmacodynamic Effects: Assessment of Androgen Receptor Signaling as Measured by Intensity of Androgen Receptor Immunohistochemical (IHC) Staining

    To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens. Androgen receptor (AR) was a type of nuclear receptor that was activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Androgen receptor (AR) signaling represented the major therapeutic target for treating metastatic prostate cancer. Assessment of androgen receptor signaling was measured by intensity of androgen receptor IHC staining and were graded as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong). Percentage of participants within each grade are reported below.

    Time frame: Day 180

  24. Serum Dihydrotestosterone (DHT): Baseline

    Time frame: Baseline

  25. Serum Dihydrotestosterone (DHT): Day 180

    Time frame: Day 180

  26. Change From Baseline in Serum Dihydrotestosterone (DHT) at Day 180

    To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.

    Time frame: Day 180

  27. Serum Testosterone: Baseline

    Time frame: Baseline

  28. Serum Testosterone: Day 180

    Time frame: Day 180

  29. Change From Baseline in Serum Testosterone at Day 180

    To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.

    Time frame: Day 180

  30. Number of Participants With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: From baseline up to 210 days

07

Results

Posted Apr 10, 2015

Participant flow

Participant flow — Overall Study
MilestoneEnzalutamide + Leuprolide + DutasterideEnzalutamide
Started2527
Completed2325
Not completed22
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryPathologic Complete Response Rate

Pathologic complete response rate was defined as percentage of participants with pathologic complete response. Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 180 days prior to prostatectomy in participants with localized prostate cancer. Pathologic complete response was defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as assessed by the local and central pathologist.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Pathologic Complete Response Rate
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Local pathologist8.7 (1.1 to 28.0)0.0 (0.0 to 13.7)
Central pathologist4.3 (0.1 to 21.9)0.0 (0.0 to 13.7)
SecondaryPercentage of Participants With Positive Surgical Margins

To determine the percentage of participants with positive surgical margins at prostatectomy as assessed by the local and central pathologist. Surgical margin, also known as tumor free margin referred to the visible normal tissue or skin margin that was removed with the surgical excision of a tumor, growth, or malignancy. The margin was described as positive when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Surgical Margins
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Local pathologist4.3 (0.1 to 21.9)12.0 (2.5 to 31.2)
Central pathologist21.7 (7.5 to 43.7)16.0 (4.5 to 36.1)
SecondaryPercentage of Participants With Extracapsular Extension: Local Review

To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the local pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Extracapsular Extension: Local Review
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Percentage of Participants With Extracapsular Extension: Local Review26.1 (10.2 to 48.4)36.0 (18.0 to 57.5)
SecondaryPercentage of Participants With Extracapsular Extension: Central Review

To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the central pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Extracapsular Extension: Central Review
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Percentage of Participants With Extracapsular Extension: Central Review56.5 (34.5 to 76.8)70.8 (48.9 to 87.4)
SecondaryPercentage of Participants With Positive Seminal Vesicles

To determine the percentage of participants with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist. Seminal vesicles or seminal glands, were defined as a pair of simple tubular glands located within the pelvis. They secrete fluid that partly composes the semen. Seminal vesicles with cancer cells in them were called positive seminal vesicles.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Seminal Vesicles
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Local pathologist30.4 (13.2 to 52.9)36.0 (18.0 to 57.5)
Central pathologist30.4 (13.2 to 52.9)36.0 (18.0 to 57.5)
SecondaryPercentage of Participants With Positive Lymph Nodes

To determine the percentage of participants with positive lymph nodes at prostatectomy as assessed by the local and central pathologist. Lymph nodes were small clumps of immune cells that act as filters for the lymphatic system. Lymph nodes with cancer cells in them were called positive lymph nodes.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Lymph Nodes
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Local pathologist26.1 (10.2 to 48.4)4.0 (0.1 to 20.4)
Central pathologist26.1 (10.2 to 48.4)4.0 (0.1 to 20.4)
SecondaryProstate-Specific Antigen (PSA) Nadir

To determine the effects on PSA as measured by the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.

Time frame:
Day 195
Reported as:
Median · microgram per liter (mcg/L)
Prostate-Specific Antigen (PSA) Nadir
microgram per liter (mcg/L)Enzalutamide + Leuprolide + DutasterideEnzalutamide
Prostate-Specific Antigen (PSA) Nadir0.04 (0.01 to 0.53)0.51 (0.02 to 8.80)
SecondaryTime to Prostate-Specific Antigen (PSA) Nadir

To determine the effects on PSA as measured by the time to the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.

Time frame:
Day 195
Reported as:
Median · days
Time to Prostate-Specific Antigen (PSA) Nadir
daysEnzalutamide + Leuprolide + DutasterideEnzalutamide
Time to Prostate-Specific Antigen (PSA) Nadir5.09 (2.79 to 6.44)6.01 (2.89 to 6.64)
SecondaryPercentage of Participants With Reduction in Prostate-Specific Antigen (PSA)

To determine the effects on PSA as measured by the percentage of participants with PSA less than (\<) 0.2 nanogram per milliliter (ng/mL), and a 50 percent (%) and 90% decrease in PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland.

Time frame:
Day 195
Reported as:
Number · percentage of participants
Percentage of Participants With Reduction in Prostate-Specific Antigen (PSA)
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
PSA < 0.2 ng/mL92.0 (74.0 to 99.0)29.6 (13.8 to 50.2)
50% decrease in PSA100.0 (86.3 to 100.0)100.0 (87.2 to 100.0)
90% decrease in PSA100.0 (86.3 to 100.0)63.0 (42.4 to 80.6)
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score

EPIC sexual domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. Sexual domain summary score was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function and satisfaction. Best change from baseline category in EPIC sexual domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened1110
Stable46
Improved10
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score

EPIC sexual function subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual function subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function. Best change from baseline category in EPIC sexual function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened1112
Stable45
Improved00
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score

EPIC sexual bother subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual bother subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing less sexual bother and difficulty. Best change from baseline category in EPIC sexual bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened75
Stable97
Improved04
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score

EPIC Hormonal Domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened1010
Stable37
Improved31
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score

EPIC hormonal function subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal function subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened1111
Stable27
Improved30
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score

EPIC hormonal bother subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal bother subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing less hormonal bothering. Best change from baseline category in EPIC hormonal bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened96
Stable511
Improved21
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 General Health Domain Score

The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The general health domain score contained 1 item scored on a scale of 1 to 5 where 1=excellent to 5=poor health, where higher score indicated worse health status. Best change from baseline category in general health domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 General Health Domain Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened55
Stable96
Improved27
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Physical Functioning Domain Score

The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The physical functioning domain score contained 2 items each scored on a scale of 1 to 5 where 1=excellent physical functioning to 5=poor physical functioning. Physical functioning domain total score ranged from 1 to 10, where higher scores indicated poor physical functioning. Best change from baseline category in physical functioning domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Physical Functioning Domain Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened32
Stable1215
Improved11
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Role-Emotional Domain Score

The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5, where higher scores indicated worse mental status. The total score ranged from 1 to 10, where higher scores indicated worse mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Role-Emotional Domain Score
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened31
Stable910
Improved47
SecondaryHealth-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Mental Component Summary

The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5 where for 1 item 1=all of the time person felt calm and peaceful to 5=none of the time person felt calm and peaceful. The score ranged from 1 to 5, where higher scores meant worse mental status. For other item 1=all of the time person felt downhearted and blue to 5=none of the time person felt downhearted and blue. The score ranged from 1 to 5, where higher scores meant better mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.

Time frame:
Day 180
Reported as:
Number · participants
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Mental Component Summary
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Worsened41
Stable811
Improved45
SecondaryPharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)

To determine pharmacodynamic effects as measured by the amount of tissue DHT in prostatectomy specimens following radical prostatectomy.

Time frame:
Day 180
Reported as:
Mean · picogram per milligram
Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)
picogram per milligramEnzalutamide + Leuprolide + DutasterideEnzalutamide
Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)0.04 ± 0.013.34 ± 1.57
SecondaryPharmacodynamic Effects: Tissue Testosterone

To determine pharmacodynamic effects as measured by the amount of tissue testosterone in prostatectomy specimens following radical prostatectomy.

Time frame:
Day 180
Reported as:
Mean · picogram per milligram
Pharmacodynamic Effects: Tissue Testosterone
picogram per milligramEnzalutamide + Leuprolide + DutasterideEnzalutamide
Pharmacodynamic Effects: Tissue Testosterone0.18 ± 0.130.90 ± 0.86
SecondaryPharmacodynamic Effects: Assessment of Apoptosis

To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens. Apoptosis was a process of biochemical events that lead to characteristic cell changes and death.

Time frame:
Day 180

No measurements were reported for this outcome.

SecondaryPharmacodynamic Effects: Assessment of Mitotic Index

Assessment was performed to determine the effects of triplet therapy and enzalutamide alone on mitotic index. Mitotic index was defined as the ratio between the numbers of cells in a population undergoing mitosis to the number of cells in a population not undergoing mitosis in prostatectomy specimens.

Time frame:
Day 180
Reported as:
Mean · ratio
Pharmacodynamic Effects: Assessment of Mitotic Index
ratioEnzalutamide + Leuprolide + DutasterideEnzalutamide
Pharmacodynamic Effects: Assessment of Mitotic Index0.9 ± 1.512.6 ± 2.81
SecondaryPharmacodynamic Effects: Assessment of Androgen Receptor Signaling as Measured by Intensity of Androgen Receptor Immunohistochemical (IHC) Staining

To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens. Androgen receptor (AR) was a type of nuclear receptor that was activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Androgen receptor (AR) signaling represented the major therapeutic target for treating metastatic prostate cancer. Assessment of androgen receptor signaling was measured by intensity of androgen receptor IHC staining and were graded as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong). Percentage of participants within each grade are reported below.

Time frame:
Day 180
Reported as:
Number · percentage of participants
Pharmacodynamic Effects: Assessment of Androgen Receptor Signaling as Measured by Intensity of Androgen Receptor Immunohistochemical (IHC) Staining
percentage of participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
00.00.0
15.60.0
227.85.3
366.794.7
SecondarySerum Dihydrotestosterone (DHT): Baseline
Time frame:
Baseline
Reported as:
Median · ng/mL
Serum Dihydrotestosterone (DHT): Baseline
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Serum Dihydrotestosterone (DHT): Baseline0.34 (0.08 to 0.58)0.29 (0.16 to 0.85)
SecondarySerum Dihydrotestosterone (DHT): Day 180
Time frame:
Day 180
Reported as:
Median · ng/mL
Serum Dihydrotestosterone (DHT): Day 180
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Serum Dihydrotestosterone (DHT): Day 1800.01 (0.01 to 0.04)0.51 (0.10 to 1.10)
SecondaryChange From Baseline in Serum Dihydrotestosterone (DHT) at Day 180

To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.

Time frame:
Day 180
Reported as:
Median · ng/mL
Change From Baseline in Serum Dihydrotestosterone (DHT) at Day 180
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Change From Baseline in Serum Dihydrotestosterone (DHT) at Day 180-0.33 (-0.57 to -0.07)0.25 (-0.16 to 0.71)
SecondarySerum Testosterone: Baseline
Time frame:
Baseline
Reported as:
Median · ng/mL
Serum Testosterone: Baseline
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Serum Testosterone: Baseline4.10 (0.77 to 6.77)3.69 (2.00 to 7.91)
SecondarySerum Testosterone: Day 180
Time frame:
Day 180
Reported as:
Median · ng/mL
Serum Testosterone: Day 180
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Serum Testosterone: Day 1800.12 (0.05 to 0.29)9.76 (1.99 to 16.63)
SecondaryChange From Baseline in Serum Testosterone at Day 180

To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.

Time frame:
Day 180
Reported as:
Median · ng/mL
Change From Baseline in Serum Testosterone at Day 180
ng/mLEnzalutamide + Leuprolide + DutasterideEnzalutamide
Change From Baseline in Serum Testosterone at Day 180-4.00 (-6.67 to -0.67)5.74 (-1.94 to 12.29)
SecondaryNumber of Participants With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame:
From baseline up to 210 days
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation
participantsEnzalutamide + Leuprolide + DutasterideEnzalutamide
Permanent Discontinuation of Enzalutamide00
Temporary Interruption of Enzalutamide30
Dose Reduction of Enzalutamide00
Study Drug Discontinuation00

Adverse events

Collected over From baseline to 30 days after the last dose of study drug, up to 210 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide + Leuprolide + Dutasteride—3/25 (12%)25/25 (100%)
Enzalutamide—2/27 (7.4%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventEnzalutamide + Leuprolide + DutasterideEnzalutamide
Postoperative ileusInjury, poisoning and procedural complications1/250/27
Clostridial infectionInfections and infestations1/250/27
LymphoceleVascular disorders1/251/27
Pelvic abscessInfections and infestations0/251/27
Most frequent other events
Showing 10 of 55
Most frequent other events
EventEnzalutamide + Leuprolide + DutasterideEnzalutamide
Hot flushVascular disorders24/257/27
FatigueGeneral disorders15/2519/27
GynaecomastiaReproductive system and breast disorders3/2517/27
InsomniaPsychiatric disorders9/256/27
Breast tendernessReproductive system and breast disorders2/259/27
Libido decreasedPsychiatric disorders8/254/27
Breast painReproductive system and breast disorders0/257/27
DiarrhoeaGastrointestinal disorders6/255/27
PollakiuriaRenal and urinary disorders6/254/27
Erectile dysfunctionReproductive system and breast disorders2/256/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Enzalutamide + Leuprolide + DutasterideEnzalutamideTotal
Mean60.8 ± 6.9561.4 ± 7.6561.1 ± 7.26
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide + Leuprolide + DutasterideEnzalutamideTotal
Female000
Male252752
08

Study locations

4 sites
  • Boston, Massachusetts 02215, United States
  • Seattle, Washington 98195, United States
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Toronto, Ontario M5G 2M9, Canada
09

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Nov 2013, 19 months.

Results were first posted in Apr 2015, 1 year 4 months after primary completion. A results delay was requested in Dec 2014.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 19 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2012
First posted
Mar 7, 2012
StartActual
Mar 31, 2012
Primary completionActual
Nov 30, 2013
CompletionActual
Nov 30, 2013
Results delay requested
Dec 19, 2014
Results first posted
Apr 10, 2015
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01547299
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Mar 31, 2012
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013
Results posted
Apr 10, 2015
Last update
Oct 23, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion